- Home
- RMCO vs PMCB Comparison
RMCO vs PMCB Comparison
Compare RMCO & PMCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMCO
- PMCB
- Stock Information
- Founded
- RMCO 2021
- PMCB 1996
- Country
- RMCO United States
- PMCB United States
- Employees
- RMCO N/A
- PMCB 2
- Industry
- RMCO Multi-Sector Companies
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RMCO Miscellaneous
- PMCB Health Care
- Exchange
- RMCO Nasdaq
- PMCB Nasdaq
- Market Cap
- RMCO 14.8M
- PMCB 11.4M
- IPO Year
- RMCO N/A
- PMCB N/A
- Fundamental
- Price
- RMCO $1.18
- PMCB $1.64
- Analyst Decision
- RMCO
- PMCB
- Analyst Count
- RMCO 0
- PMCB 0
- Target Price
- RMCO N/A
- PMCB N/A
- AVG Volume (30 Days)
- RMCO 39.4K
- PMCB 14.0K
- Earning Date
- RMCO 01-24-2025
- PMCB 12-24-2024
- Dividend Yield
- RMCO N/A
- PMCB N/A
- EPS Growth
- RMCO N/A
- PMCB N/A
- EPS
- RMCO N/A
- PMCB 0.74
- Revenue
- RMCO $568,896.00
- PMCB N/A
- Revenue This Year
- RMCO N/A
- PMCB N/A
- Revenue Next Year
- RMCO N/A
- PMCB N/A
- P/E Ratio
- RMCO N/A
- PMCB $2.21
- Revenue Growth
- RMCO 21.05
- PMCB N/A
- 52 Week Low
- RMCO $0.70
- PMCB $1.39
- 52 Week High
- RMCO $4.75
- PMCB $2.58
- Technical
- Relative Strength Index (RSI)
- RMCO 61.39
- PMCB 45.24
- Support Level
- RMCO $0.96
- PMCB $1.60
- Resistance Level
- RMCO $1.28
- PMCB $1.69
- Average True Range (ATR)
- RMCO 0.11
- PMCB 0.11
- MACD
- RMCO 0.02
- PMCB -0.00
- Stochastic Oscillator
- RMCO 73.68
- PMCB 40.00
About RMCO Royalty Management Holding Corporation
Royalty Management Holding Corp formed to invest or purchase assets that have current or near-term income to provide the company with accretive cash flow from which it can reinvest in new assets or expand cash flow from existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.